INTRODUCTION
The incidence of ectopic pregnancy has been increasing in developed countries (1) . However, the possibility of early detection has significantly decreased disease related morbidity and mortality. In the treatment of disease process, there has been a shift from surgery to medical therapy (2) The purpose of this study is to investigate the prognostic factors affecting the success on patients diagnosed ectopic pregnancy and treated medically single-dose methotrexate during a ten-year period in our clinic. Between day 4 and day 7 of treatment, ß-hCG falling more than 15% in value, patients were followed up three times until <5m›u/ml and these patients were Differences among groups were considered to be significant if the P value was < 0.05.
MATERIALS AND METHODS

In
RESULTS
A total of 222 patients diagnosed and treated ectopic pregnancy were subjected to evaluation between January 2000 -January 2010. As initial therapy, 99 patients were treated with a single dose of methotrexate.
The average age of patients was 30.72 ± 5.76, at the time of diagnosis of gestational week was 6.7 ± 1.0 weeks, ectopic pregnancy size was 22.07 ± 13.32 mm, serum ß-hCG level was 2196 ± 2603 mIU/ml (Table   I ). While single-dose methotrexate therapy was successful in 67 (% 67.6) patients, it was unsuccessful 32 in (32.3%) patients. Single-dose methotrexate for patients' (with and without success) demographic, clinical and laboratory features are shown in Table II. Between the groups, no difference was observed in terms of age, parity, abortion, hospital admission weeks of pregnancy, ectopic pregnancy size. However, in the second group, serum ß-hCG values were significantly higher than the first group (The first group of median ß-hCG value: 819 (122-3822) mIU / mL, the second group of median ß-hCG value 3562 (642-18000) mIU / mL, p < 0.001), also median gravidity and curretage values were significantly higher than the first group.
The risk factors for ectopic pregnancy were compared for first and second groups at Table III. There was no difference in terms of the parameters measured. The use of single-dose methotrexate for ectopic pregnancy are in clinical use since the 1990s (8, 9) .
Success rates ranged from 64% to 94.2% (4, (10) (11) (12) (13) (14) (15) . In our study, the success rate was consistent with success rates of different studies in the literature (67.7%). Initial ß-hCG level was found 2196±2603 mIU/ml. 9 of 32 patients who failed were treated second dose methotrexate and 23 patients were treated surgically.
In the study by Adal› et al, single-dose methotrexate therapy was found to be successful 14 in 18 patients (% 77.7). Initial ß-hCG level was determied as 2615±2064 mIU/ml. 4 patients underwent surgery after a failed single dose methotrexate therapy (16) . In the study by Turhan et al, same treatment was found to be successful 9 in 11 patients (81.8%). Initial ß-hCG level was determied as 1664±1571 mIU/ml. The second dose methotrexate treatment was needed for 2 patients (18.2%) who failed (17) . In the study by Alk›fl et al, same treatment was found to be successful 81 in 98 patients (82.7%) and rest of the failed 17 patients (%17.3) underwent surgery. Initial ß-hCG level was determied as 1592±2613 mIU/ml (18) .
In patients with ectopic pregnancy, reports on prognostic factors to successful response to single-dose methotrexate therapy are limited. In two previous studies in a manner similar to ours, high serum ß-hCG levels has been identified as a single prognostic factor (6, 19) . while in the study by Kimiaei et al, on top of initial ß-hCG values, ectopic focus size was determined to be significant in determining the effectiveness of single-dose methotrexate therapy (20) . Also in some studies, in addition to the height of initial ß-hCG values, initial and after methotrexate, fourth day, value of the decline at the ß-hCG level was the most important indicators in predicting success (21, 22) . Moreover, in
